862 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Better Buy: Celgene Corporation vs. Merck & Co., Inc. https://www.fool.com/investing/2017/04/25/better-buy-celgene-corporation-vs-merck-co-inc.aspx?source=iedfolrf0000001 Apr 25, 2017 - Which drug stock wins in a head-to-head matchup between Celgene and Merck?
Tesaro Inc Bulls Need a Reality Check https://www.fool.com/investing/2017/04/25/tesaro-inc-bulls-need-a-reality-check.aspx?source=iedfolrf0000001 Apr 25, 2017 - Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?
Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales https://www.fool.com/investing/2017/05/02/gilead-sciences-incs-revenue-and-earnings-continue.aspx?source=iedfolrf0000001 May 02, 2017 - The big biotech's revenue and earnings fell yet again in Q1. But there were a few bright spots.
Here's Why ImmunoGen Rose 10.7% in April https://www.fool.com/investing/2017/05/03/why-immunogen-rose-107-in-april.aspx?source=iedfolrf0000001 May 03, 2017 - It was a quiet month for the beleaguered biotech, but a few actions by Wall Street analysts caused the share price to climb by double digits.
Big Pharma Diabetes Drugs Not So Sweet. What's in Store? http://www.zacks.com/stock/news/262544/big-pharma-diabetes-drugs-not-so-sweet-whats-in-store?cid=CS-ZC-FT-262544 May 31, 2017 - Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
4 Reasons Teva Pharmaceutical Industries Ltd. Gained 21% in June https://www.fool.com/investing/2017/07/06/4-reasons-teva-pharmaceutical-industries-ltd-gaine.aspx?source=iedfolrf0000001 Jul 06, 2017 - Sometimes, no news is good news for a troubled drugmaker.
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August https://www.fool.com/investing/2017/09/05/the-key-reason-incyte-corporation-added-850-millio.aspx?source=iedfolrf0000001 Sep 05, 2017 - An update on bariticinib's review timeline has Wall Street rightly excited.
3 Small-Cap Biotech Stocks to Buy This Fall https://www.fool.com/investing/2017/09/21/3-small-cap-biotech-stocks-to-buy-this-fall.aspx?source=iedfolrf0000001 Sep 21, 2017 - Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.
Shares of Bristol-Myers Falling After Failed Study, While Its Rival Is Surging http://www.zacks.com/stock/news/227117/shares-of-bristol-myers-falling-after-failed-study-while-its-rival-is-surging?cid=CS-ZC-FT-227117 Aug 05, 2016 - Shares of Bristol-Myers were falling in morning trade Friday after one of their drugs didn't reach the levels they were hoping for, while its rival Merck saw its shares climb as its competing drug was more successful in the same trial earlier this year.
Should Gilead Sciences Acquire NewLink Genetics? https://www.fool.com/investing/2017/04/21/gilead-sciences-should-acquire-newlink-genetics.aspx?source=iedfolrf0000001 Apr 21, 2017 - NewLink Genetics intriguing IDO-inhibitors could make it a target of Gilead Sciences.

Pages: 12345678910...87

<<<Page 5>